Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

References

• US FDALemtrada: Prescribing Information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdfAccessed June 16, 2017
   Google Scholar
• EMASummary of Product of Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/003718/WC500150521.pdfAccessed June 16, 2017
   Google Scholar
• ColesAJWingMGMolyneuxPMonoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosisAnn Neurol199946329630410482259
   PubMed Web of Science ®Google Scholar
• MoreauTThorpeJMillerDPreliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosisLancet199434489182983017914262
   PubMed Web of Science ®Google Scholar
• ColesADeansJCompstonACampath-1H treatment of multiple sclerosis: lessons from the bedside for the benchClin Neurol Neurosurg2004106327027415177782
   PubMed Web of Science ®Google Scholar
• HirstCLPaceAPickersgillTPCampath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosisJ Neurol2008255223123818283404
   PubMed Web of Science ®Google Scholar
• InvestigatorsCTColesAJCompstonDAAlemtuzumab vs. interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet201238098561829183923122650
   PubMed Web of Science ®Google Scholar
• GiovannoniGCohenJAColesAJAlemtuzumab improves preexisting disability in active relapsing-remitting MS patientsNeurology201687191985199227733571
   PubMed Web of Science ®Google Scholar
• TuohyOCostelloeLHill CawthorneGAlemtuzumab treatment of multiple sclerosis: long-term safety and efficacyJ Neurol Neurosurg Psychiatry201586220821524849515
   PubMed Web of Science ®Google Scholar
• ColesAJFoxEVladicAAlemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trialNeurology201278141069107822442431
   PubMed Web of Science ®Google Scholar
• ArnoldDTraboulseeAColesADurable Effect of Alemtuzumab on MRI Activity in Treatment-Naive Active Relapsing-Remitting Multiple Sclerosis Patients: 4-Year Follow-up of CARE-MS INeurologyPresented at the AAN Meeting 2015 in Washington Neurology2015
   Google Scholar
• TraboulseeAColesACohenJDurable Effect of Alemtuzumab on MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS IINeurology20158414 SupplementPresented at the AAN Meeting 2015 in Washington2015
   Google Scholar
• La GankeCHBBerkovichRDurable effect of alemtuzumab on disability improvement in patients with relapsing-remitting multiple sclerosis who relapsed on a prior therapyNeurologyPresented at the AAN Meeting 2015 in Washington. Neurology2015
   Google Scholar
• KalincikTBrownJWRobertsonNTreatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyLancet Neurol201716427128128209331
   PubMed Web of Science ®Google Scholar
• CaonCNameyMMeyerCPrevention and management of infusion-associated reactions in the comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis (CARE-MS) programInt J MS Care201517419119826300705
   PubMedGoogle Scholar
• Genzyme TherapeuticsLEMTRADA Summary of Product CharacteristicsOxfordGenzyme Therapeutics Ltd2013
   Google Scholar
• BreslinSCytokine-release syndrome: overview and nursing implicationsClin J Oncol Nurs2007111 suppl374217471824
   PubMedGoogle Scholar
• MaggiEVultaggioAMatucciAAcute infusion reactions induced by monoclonal antibody therapyExpert Rev Clin Immunol201171556321162650
   PubMed Web of Science ®Google Scholar
• NameyMHalperJO’LearySBeavinJBishopCBest practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapiesJ Infus Nurs20103329811120228647
   PubMedGoogle Scholar
• RanganathanUKaunznerUFosterSVartanianTPerumalJSImmediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosisMult Scler 1352458517699876. Epub201731
   Web of Science ®Google Scholar
• HensonLJArnoldDLCohenJAIncidence of infection decreases over time in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis: 4-year follow-up of the CARE-MS studiesProceedings of the AAN MeetingApril 18–25, 2015Washington, DC, USA
   Google Scholar
• PenkertHDelbridgeCWantiaNWiestlerBKornTFulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosisJAMA Neurol201673675775927043129
   PubMed Web of Science ®Google Scholar
• Sheikh-TahaMCormanLCPulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosisMult Scler201723687287428290754
   PubMed Web of Science ®Google Scholar
• HavrdovaEHorakovaDKovarovaIAlemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useTher Adv Neurol Disord201581314525584072
   PubMed Web of Science ®Google Scholar
• HaleGBrightSChumbleyGRemoval of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complementBlood19836248738826349718
   PubMed Web of Science ®Google Scholar
• JacobsPWoodLFullardLWaldmannHHaleGT cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host diseaseBone Marrow Transplant19941367637697920312
   PubMed Web of Science ®Google Scholar
• LinTSDonohueKAByrdJCConsolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101J Clin Oncol201028294500450620697069
   PubMed Web of Science ®Google Scholar
• RauDLangMHarthAListeria meningitis complicating alemtuzumab treatment in multiple sclerosis – report of two casesInt J Mol Sci2015167146691467626132570
   PubMed Web of Science ®Google Scholar
• ClericoMDe MercantiSArtusiCADurelliLNaismithRTActive CMV infection in two patients with multiple sclerosis treated with alemtuzumabMult Scler201723687487628290755
   PubMed Web of Science ®Google Scholar
• JonesJLPhuahCLCoxALIL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)J Clin Invest200911972052206119546505
   PubMed Web of Science ®Google Scholar
• DanielsGHVladicABrinarVAlemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosisJ Clin Endocrinol Metab2014991808924170099
   PubMed Web of Science ®Google Scholar
• ObermannMRuckTPfeufferSBaumJWiendlHMeuthSGSimultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosisMult Scler20162291235124126980848
   PubMed Web of Science ®Google Scholar
• LEMTRADALEMTRADA REMS Program Overview Available from: https://www.lemtradarems.com/Docs/Pdf/LEMTRADA_REMS_Program_Overview.pdfAccessed August 1, 2015
   Google Scholar
• JonesJLColesAJMode of action and clinical studies with alemtuzumabExp Neurol2014262Pt A374324792641
   PubMed Web of Science ®Google Scholar
• MeyerDColesAOyuelaPPurvisAMargolinDHCase report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosisMult Scler2013216063
   Web of Science ®Google Scholar
• AzzopardiLThompsonSAJHardingKEPredicting autoimmunity after alemtuzumab treatment of multiple sclerosisJ Neurol Neurosurg Psychiatry201485779579824368840
   PubMed Web of Science ®Google Scholar
• MetzIRieckmannPKallmannB-ABruckWDisseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosisActa Neuropathol Commun2016418127503238
   PubMed Web of Science ®Google Scholar
• PandeARAndoKIshikuraRDisseminated necrotizing leukoencephalopathy following chemoradiation therapy for acute lymphoblastic leukemiaRadiat Med200624751551917058146
   PubMedGoogle Scholar
• SakamakiHOnozawaYYanoYDisseminated necrotizing leukoencephalopathy following irradiation and methotrexate therapy for central nervous system infiltration of leukemia and lymphomaRadiat Med19931141461538234858
   PubMedGoogle Scholar
• RaghavendraSNairMDChemmanamTKrishnamoorthyTRadhakrishnanVVKuruvillaADisseminated necrotizing leukoencephalopathy following low-dose oral methotrexateEur J Neurol200714330931417355553
   PubMed Web of Science ®Google Scholar
• SharsharTGrayFPoronFRaphaelJCGajdosPAnnaneDMultifocal necrotizing leukoencephalopathy in septic shockCrit Care Med200230102371237512394971
   PubMed Web of Science ®Google Scholar
• PerryASchmidtRECancer therapy-associated CNS neuropathology: an update and review of the literatureActa Neuropathol2006111319721216463065
   PubMed Web of Science ®Google Scholar
• MillerTHabekMColesAAnalysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancyPresented at 2014 Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple SclerosisSeptember 2014Boston, MA
   Google Scholar
• LecumberriBArnoldDACohenJADetection of thyroid malignancies in alemtuzumab-treated patients in the multiple sclerosis clinical development programEuropean Committee for Treatment and Research in Multiple Sclerosis2015Barcelona
   Google Scholar
• WillisMDRobertsonNPAlemtuzumab for multiple sclerosisCurr Neurol Neurosci Rep20161698427485945
   PubMed Web of Science ®Google Scholar
• ColesAJAlemtuzumab treatment of multiple sclerosisSemin Neurol2013331667323709214
   PubMed Web of Science ®Google Scholar
• IbitoyeRWilkinsAThyroid papillary carcinoma after alemtuzumab therapy for MSJ Neurol201426191828182925082630
   PubMed Web of Science ®Google Scholar
• PaceAAZajicekJPMelanoma following treatment with alemtuzumab for multiple sclerosisEur J Neurol2009164e70e7119222552
   PubMed Web of Science ®Google Scholar
• AchironAChambersCFoxEJPregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development programMultiple Sclerosis Journal201521581582
   Web of Science ®Google Scholar